Cost–utility analysis of operative <i>versus</i> non-operative treatment for colorectal liver metastases

Roberts, KJ; Sutton, Andrew; Prasad, K. Raj; Toogood, Giles J.; Lodge, J. Peter A.

doi:10.1002/bjs.9761

Cited by 14 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple studies show a survival benefit for patients with liver metastases with simultaneous extrahepatic metastases when comparing resection combined with perioperative chemotherapy to chemotherapy alone [39,40]. There is also evidence suggesting that local therapy yields better cost effectiveness in addition to better survival compared to systemic therapy [41]. Future analysis of the current cohort once sufficient follow-up has been reached will show whether the increased use of local therapy has impacted overall survival.…”

Section: Discussionmentioning

confidence: 93%

Treatment of metachronous colorectal cancer metastases in the Netherlands: A population-based study

Meyer

Olthof

Grünhagen

et al. 2022

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: This study aimed to describe the treatment of metachronous colorectal cancer metastases in a recent population-based cohort. Method: Patients with stage I-III colorectal cancer (CRC), diagnosed between January 1st and June 30th , 2015 who were surgically treated with curative intent were selected from the Netherlands Cancer Registry. Follow-up was at least 3 years after diagnosis of the primary tumour. Treatment of metachronous metastases was categorized into local treatment, systemic treatment, and best supportive care. Overall survival was estimated using Kaplan-Meier method. Results: Out of 5412 patients, 782 (14%) developed metachronous metastases, of whom 393 (50%) underwent local treatment (LT) with or without systemic therapy, 30% of patients underwent only systemic therapy (ST) and 19% only best supportive care (BSC). The most common metastatic site was the liver (51%) followed by lungs (33%) and peritoneum (22%). LT rates were 69%, 66%, and 44% for liver-only, lungonly and, peritoneal-only metastases respectively. Patients receiving LT and ST were significantly younger than patients receiving LT alone, while patients receiving BSC were significantly older than the other groups (p < 0.001). Patients with liver-only or lung-only metastases had a 3-year OS of 50.2% (43.3e56.7 95% CI) and 61.5% (50.7e70.6 95% CI) respectively. Patients with peritoneal-only disease had a lower 3year OS, 18.1% (10.1e28.0 95% CI). Conclusion: Patients with metastases confined to the liver and lung have the highest rates of local treatment for metachronous metastatic colorectal cancer. The number of patients who underwent local treatment is higher than reported in previous Dutch and international studies.

show abstract

Section: Discussionmentioning

confidence: 93%

Treatment of metachronous colorectal cancer metastases in the Netherlands: A population-based study

Meyer

Olthof

Grünhagen

et al. 2022

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…In such cases, the treatment recommended in the National Comprehensive Cancer Network (NCCN) guidelines consists of three possibilities: colectomy and metastasectomy + adjuvant chemotherapy; neoadjuvant chemotherapy + colectomy and metastasectomy + adjuvant chemotherapy; or colectomy + adjuvant chemotherapy + metastasectomy + adjuvant chemotherapy. The choice of treatment depends on the local availability of resources [12], [13].…”

Section: Discussionmentioning

confidence: 99%

Perforation of the cecum resulting from a closed-loop obstruction in a patient with an adenocarcinoma of the sigmoid colon: a case report

Toledo

Correia

Coutinho

et al. 2017

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

HighlightsBowel obstruction is one of the principal non-traumatic causes of general surgery emergencies, both in Brazil and worldwide.The progression of bowel obstruction, particularly when the ileocecal valve is competent, may result in excessive dilatation of the cecum.A syndromic diagnosis of bowel obstruction was made, and the patient was referred for CT.The estimates of the Brazilian National Cancer Institute (INCA) for this country in 2016 were around 16,660 new cases in men and 17,620 in women.Colorectal cancer is one of the most common forms of cancer in the elderly, perforation of the cecum occurs in only around 3–8% of cases.

show abstract

“…Operative mortality 0.00% [29] 0.00% [30,31] Patients with no progression 0.13% Calibrated from de Haas et al [27] 0.26% Calibrated from Lee et al [32] Patients with local progression 1.55% Calibrated from de Haas et al [27] and mortality rate for patients with other progression status 3.21% Calibrated from Grieco et al [33] Patients with regional/distant progression 3.06% Rees et al [34] 12.65% As above…”

Section: Mortality Rates (Monthly)mentioning

confidence: 99%

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

Cost–utility analysis of operative versus non-operative treatment for colorectal liver metastases

Abstract: Operative treatment of CRLMs yields greater survival than non-operative treatment, and is both more effective and less costly.

Cited by 14 publications

References 34 publications

Treatment of metachronous colorectal cancer metastases in the Netherlands: A population-based study

Treatment of metachronous colorectal cancer metastases in the Netherlands: A population-based study

Perforation of the cecum resulting from a closed-loop obstruction in a patient with an adenocarcinoma of the sigmoid colon: a case report

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma

Contact Info

Product

Resources

About